Cover image of PeerView Internal Medicine CME/CNE/CPE Audio Podcast
(14)
Science

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Updated 7 days ago

Science
Read more

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Read more

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

iTunes Ratings

14 Ratings
Average Ratings
6
3
1
2
2

AmaZing Material for internists

By Dr.Job - Jan 16 2010
Read more
I cannot describe how nice and neat it was to listen to this material. Basim Ayoub, MD

iTunes Ratings

14 Ratings
Average Ratings
6
3
1
2
2

AmaZing Material for internists

By Dr.Job - Jan 16 2010
Read more
I cannot describe how nice and neat it was to listen to this material. Basim Ayoub, MD
Cover image of PeerView Internal Medicine CME/CNE/CPE Audio Podcast

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Updated 7 days ago

Read more

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Rank #1: Adrian Hernandez, MD, MHS - Recognizing and Treating Iron Deficiency in Patients With Heart Failure: Achieving Better Outcomes and Quality of Life

Podcast cover
Read more
Go online to PeerView.com/FCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in cardiology shares insight on recognizing and treating iron deficiency in patients with heart failure to achieve better outcomes and quality of life. Upon completion of this activity, participants should be better able to: Recognize the prevalence of iron deficiency (ID) in heart failure (HF) and its impact on patient outcomes and quality of life, Identify evidence-based guidelines and the latest clinical data on the efficacy and safety of currently available and emerging iron therapies for the management of ID in patients with HF, Apply evidence-based guidelines and the latest clinical data on available and emerging iron therapies to the treatment of ID in patients with HF.
Jul 01 2019
17 mins
Play

Rank #2: Marwan Sabbagh, MD, FAAN - Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer’s Disease: What Are the Implications for Treatment?

Podcast cover
Read more
Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer’s Disease: What Are the Implications for Treatment?
Feb 19 2019
45 mins
Play

Rank #3: Michael E. Wechsler, MD - Advances in the Treatment of Uncontrolled Persistent Asthma: Expert Insights in Personalizing Patient Care

Podcast cover
Read more
Go online to PeerView.com/PBN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in asthma discuss recent advances in the treatment of uncontrolled persistent asthma and offer practical guidance on personalizing patient care. Upon completion of this activity, participants should be better able to: Describe the mechanisms of inflammatory pathways in uncontrolled persistent asthma and their implications for treatment, Assess patients with asthma for symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapies, Apply evidence-based guidelines and the latest clinical data when selecting treatment for patients with uncontrolled persistent asthma, Implement patient education and communication tactics in personalized treatment plans to improve patient adherence, self-management, and quality of life.
Aug 05 2019
43 mins
Play

Rank #4: Paul M. Ridker, MD, MPH, FACC, FAHA - Looking Beyond Lipids: A Visual Guide to Targeting Vascular Inflammation in Atherosclerosis

Podcast cover
Read more
Looking Beyond Lipids: A Visual Guide to Targeting Vascular Inflammation in Atherosclerosis
Jan 14 2019
1 hour 8 mins
Play

Rank #5: Elizabeth A. Stewart, MD - Advances in Medical Options for Uterine Fibroids and Endometriosis: Clinical Highlights From Montreal

Podcast cover
Read more
Go online to PeerView.com/NNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in gynecology/obstetrics discusses emerging data on options for the treatment of endometriosis and uterine fibroids that were presented at the 5th Congress of the Society for Endometriosis and Uterine Disorders (SEUD 2019) in Montreal in May 2019. Upon completion of this activity, participants should be better able to: Discuss the latest clinical data on current and emerging treatment options for management of endometriosis, endometriosis-associated pain, and uterine fibroids, Employ recent evidence on new and established treatment approaches for individualized therapeutic management of patients with endometriosis and uterine fibroids.
Aug 23 2019
30 mins
Play

Rank #6: Mark S. Sulkowski, MD - Addressing the Evolving Opioid and HCV Epidemics Through Community Engagement and Education

Podcast cover
Read more
Go online to PeerView.com/QYB860 to view the entire program with slides. In this activity, which is based on recent live meetings held in Baltimore and Cambridge, Maryland, clinicians practicing on the front-lines of the intersecting hepatitis C and opioid epidemics offer thought-provoking perspectives on identifying HCV among people with substance use disorders who live in urban and rural healthcare settings and successfully engaging them in care to achieve better patient and community outcomes. Upon completion of this activity, participants will be able to: Evaluate patients with, or at risk of, hepatitis C virus (HCV) infection in order to make appropriate referrals for screening, diagnosis, treatment, or follow-up, Apply evidence-based strategies for supporting patients with injection drug use in harm reduction and adhering to potential HCV treatment and monitoring regimens, Integrate patient-centered HCV education into substance abuse/addiction center visits and programs, Collaborate with addiction professionals, social workers, case managers, primary care providers, infectious disease physicians, and HCV specialists to facilitate an interdisciplinary approach to HCV care and treatment for people who inject drugs (PWID)
Mar 25 2019
1 hour 23 mins
Play

Rank #7: Deborah I. Friedman, MD, MPH - Improving the Recognition and Management of Migraine in an Era of Expanding Options for Acute Treatment and Prevention: How Is the Role of the Primary Care Clinician Evolving?

Podcast cover
Read more
Improving the Recognition and Management of Migraine in an Era of Expanding Options for Acute Treatment and Prevention: How Is the Role of the Primary Care Clinician Evolving?
Dec 05 2018
35 mins
Play

Rank #8: Stewart J. Tepper, MD, FAHS - Exploring the Latest Evidence on New and Emerging Therapies for Migraine Prevention: What Are the Potential Implications on Clinical Practice?

Podcast cover
Read more
Exploring the Latest Evidence on New and Emerging Therapies for Migraine Prevention: What Are the Potential Implications on Clinical Practice?
Dec 10 2018
1 hour 1 min
Play

Rank #9: John E. Anderson, MD - Realizing Your Patient’s Potential: Embracing the Guidelines to Appropriately Individualize Care for Patients With Type 2 Diabetes

Podcast cover
Read more
Go online to PeerView.com/UQE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in internal medicine offers insight on providing patient-centered diabetes care and developing individualized treatment plans for patients with type 2 diabetes mellitus (T2DM). Upon completion of this activity, participants should be better able to: Recognize the primary goals of treatment and key components involved in providing effective patient-centered care to individuals with T2DM, Apply recommendations offered in current evidence-based guidelines to appropriately individualize antihyperglycemic therapy for patients with T2DM.
May 06 2019
32 mins
Play

Rank #10: Jonathan Corren, MD and Paul Yamauchi, MD - Advances in the Management of Allergic and Inflammatory Diseases: Highlights From Washington, DC and San Francisco

Podcast cover
Read more
Go online to PeerView.com/NCE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in allergy and dermatology discuss advances in the management of allergic and inflammatory diseases presented at the 2019 American Academy of Dermatology Annual Meeting and the American Academy of Allergy, Asthma & Immunology 2019 Annual Meeting. Upon completion of this activity, participants will be able to: Describe the relationship between type 2 inflammatory disorders, including atopic dermatitis, asthma, chronic rhinosinusitis and nasal polyps (CRS/NP), and eosinophilic esophagitis (EoE), Discuss emerging data related to the efficacy and safety of therapies for the treatment of allergic and inflammatory diseases, Apply the latest clinical data to the treatment of patients with allergic and inflammatory disorders, such as atopic dermatitis, asthma, CRS/NP, and EoE.
Apr 29 2019
39 mins
Play

Rank #11: John B. Buse, MD, PhD - An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Disease in Patients With Type 2 Diabetes

Podcast cover
Read more
Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.
Jul 05 2019
40 mins
Play

Rank #12: Marc S. Sabatine, MD, MPH - Following the Evidence: LDL-C as a Path to Reducing Cardiovascular Events—How Low Do We Go?

Podcast cover
Read more
Following the Evidence: LDL-C as a Path to Reducing Cardiovascular Events—How Low Do We Go?
Jan 02 2019
1 hour 17 mins
Play

Rank #13: Luciano J. Costa, MD, PhD - Exploring Clinical Decisions in the New Era of Myeloma Management: The Impact of Novel Platforms and Agent Classes Across the Spectrum of Care

Podcast cover
Read more
Go online to PeerView.com/WPW860 to view the entire program with slides. In this activity, an expert in multiple myeloma discusses newer safety and efficacy data surrounding novel and emerging therapeutic drug classes for multiple myeloma, including agents directed against intracellular targets and immune-based treatment. The activity will also include expert insights on how to develop effective, individualized treatment strategies with novel components that are informed by clinical findings and how to manage treatment-related adverse effects associated with emerging agent classes. Upon completion of this activity, participants should be better able to: Cite updated data about the efficacy and safety of novel agent classes and next-generation therapeutics in multiple myeloma, including proteasome inhibitors, IMiDs, novel antibodies, immunotherapies, and epigenetic agents, among others, Develop customized therapy for patients with newly diagnosed multiple myeloma, including elderly patients, individuals eligible or ineligible for stem-cell transplant, and those requiring maintenance therapy post-transplant, Select regimens adapted to the needs of patients with previously treated multiple myeloma, including those with early relapse or relapsed/refractory multiple myeloma, Manage treatment-related adverse events in patients with multiple myeloma receiving therapy with novel or next-generation agent classes.
Mar 20 2019
32 mins
Play

Rank #14: Edward J. Fox, MD, PhD - Personalizing Disease-Modifying Therapy for Multiple Sclerosis in the Era of Expanding Treatment Options and Potential Biomarkers

Podcast cover
Read more
Go online to PeerView.com/EHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Several disease-modifying therapies (DMTs) are now approved for MS management, and a number of emerging therapies are under investigation for the treatment of this disease. In this unique PeerView Talks activity, based on a live symposium held at the 2019 CMSC Annual Meeting, leading experts engage in a live discussion of current data on available and investigational therapies for the treatment of MS, as well as how to personalize DMT selection. The faculty share their personal experiences and the “Stories Behind the Science” that connect the evidence to real-world clinical practice. Upon completion of this activity, participants will be able to: Apply available data on approved disease-modifying therapies when managing patients with multiple sclerosis, Identify recent data on the efficacy, safety, and tolerability of emerging disease-modifying therapies for the treatment of multiple sclerosis, Cite current data on potential markers that may correlate with disease activity and severity and treatment response, Select an optimal course of disease-modifying therapy for individuals with MS according to their level of disease activity, preferences, and other factors.
Jul 17 2019
49 mins
Play

Rank #15: Robert Z. Orlowski, MD, PhD - Driving Change in Multiple Myeloma: Updates on Novel Agent Classes and Next-Generation Therapeutics

Podcast cover
Read more
Go online to PeerView.com/TXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in the management of MM discusses the implications of recent efficacy and safety data that support the ongoing integration and use of several innovative treatments, such as antibody-based therapies, next-generation IMiDs and proteasome inhibitors, and novel therapies directed against intracellular targets. The expert also provides a review of the overall shape of MM therapy in newly diagnosed and relapsed disease, and discusses strategies to manage treatment-related adverse effects. Upon completion of this activity, participants will be able to: Summarize updated evidence on the use of novel agent classes and next-generation therapeutics in multiple myeloma (MM), including proteasome inhibitors, immunomodulators (IMiDs), novel antibodies, and targeted agents, Select appropriate therapy in patients with newly diagnosed MM, including those requiring eradication of MRD or treatment for high-risk disease, Recommend therapy with novel components for patients with early relapse or treatment-refractory MM, Manage treatment-related adverse events in patients with MM who are receiving novel therapeutics as part of their care.
Aug 14 2019
50 mins
Play

Rank #16: Christopher L. Bowlus, MD - Addressing Challenges in the Management of Primary Biliary Cholangitis: Harnessing the Clinical Potential of New Treatment Approaches to Improve Patient Outcomes

Podcast cover
Read more
Go online to PeerView.com/PST860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in autoimmune liver diseases uses a novel, interactive talk to guide learners through the diagnosis and treatment of primary biliary cholangitis. Upon completion of this activity, participants should be better able to: Incorporate appropriate tests to support the diagnosis of PBC Apply guideline-based recommendations to stratify patients at risk for progressive PBC, Outline current treatment options for PBC in the context of mechanism of action, efficacy, safety, and appropriate clinical utilization, Select therapy for individual patients with PBC based on patient-specific and disease characteristics, Employ patient-centered, long-term management strategies for patients with PBC that address extrahepatic diseases manifestations and complications of PBC.
May 29 2019
17 mins
Play

Rank #17: Johanna C. Bendell, MD - Stories From the Pancreatic Cancer CaseBook: Taking the Road to Improved Outcomes With Modern Therapeutic Concepts and Innovative Treatments

Podcast cover
Read more
Go online to PeerView.com/RRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pancreatic cancer has retained its fearsome reputation amidst the clinical advances made in recent years in other solid tumor settings, and it is now the fourth leading cause of cancer death in men and women in the United States. But recently, new science has taken important steps in meeting the challenges posed by this disease. Beginning with the validation of modern chemotherapy platforms, which now can be sequenced to improve clinical benefits, clinicians are increasingly able to select more potent—and soon, more targeted—options for disease management. In the wake of these advances, other innovative therapies are being rapidly developed, from stroma- and BRCA-targeting agents, to immunotherapy and tumor treating fields. In this PeerView CaseBook on-demand activity based on a recent live symposium held at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, our expert panel profiles the modern management of pancreatic cancer, including the evidence for more personalized approaches to treatment decision-making across the disease spectrum. The panelists highlight new directions in therapeutic sequencing, explore the role of clinical trials as a driver for validating innovative strategies, and use real-world cases to crystalize strategies for initial therapy selection and sequencing, the function of biomarker testing, and patient referral to clinical trials. This engaging CaseBook activity also highlights important “patient voice” materials developed in collaboration with Let’s Win, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let’s Win is an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize recent evidence on the use of modern cytotoxic platforms and chemotherapy sequencing approaches, targeted agents, and tumor treating field therapy, among others, in the setting of advanced pancreatic cancer, Recommend appropriate therapeutic platforms across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics, Identify patients with pancreatic cancer who are candidates for experimental therapy in a clinical trial, Manage adverse events associated with established cytotoxic and emerging therapies for pancreatic cancer.
Sep 02 2019
1 hour 38 mins
Play

Rank #18: Mollie Moran, APRN-CNP, AOCNP - Taking Aim at B-Cell Malignancies With BTK Inhibitors: Oncology Nurse Perspectives and Insights on Clinical Care

Podcast cover
Read more
Go online to PeerView.com/XAC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium held during the Oncology Nursing Society’s (ONS) 44th Annual Congress, a panel of expert nurse faculty use a MasterClass/case-forum design to offer an in-depth review of BTK inhibitors, their therapeutic applications in B-cell malignancies, and the core nurse-focused practice issues that are central to the further integration of BTK inhibitors into treatment plans for patients with cancers such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), among other B-cell disorders. Upon completion of this activity, participants will be able to: Summarize updated safety and efficacy evidence about first- and second-generation BTK inhibitors in the management of B-cell cancer, Cite dosing considerations, administration strategies, and treatment schedules of BTK inhibitors for the management of newly diagnosed or refractory/relapsed B-cell cancer, Educate patients about the varying side effect profiles, efficacy outcomes, and potential for treatment resistance associated with the use of BTK inhibitors for B-cell cancer, Manage side effect and adherence considerations in patients with B-cell cancer treated with BTK inhibitors.
May 27 2019
58 mins
Play

Rank #19: Amy L. Olson, MD, MSPH - Applying New Insights to Improve Diagnosis and Management of Interstitial Lung Diseases

Podcast cover
Read more
Go online to PeerView.com/JGG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in interstitial lung diseases offers new insights for improving the diagnosis and management of ILD. Upon completion of this activity, participants will be able to: Outline the prevalence, burden of illness, and signs and symptoms of interstitial lung disease (ILD), including IPF and SSc-ILD, Employ updated guidelines and best practices for differential diagnosis of ILD, including IPF, Evaluate current and emerging strategies for the management of ILD, including IPF and SSc-ILD, Implement evidence-based strategies to manage IPF, mitigate adverse events related to antifibrotic therapy, manage comorbid disease, and improve quality of life, Apply methods to effectively communicate and educate ILD patients about their disease.
Aug 12 2019
34 mins
Play

Rank #20: Evan J. Lipson, MD - Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED

Podcast cover
Read more
Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists
Mar 11 2019
32 mins
Play

Similar Podcasts